Advancement of duloxetine in treatment of osteoarthritis pain

doi:10.3877/cma.j.issn.1674-134X.2021.03.009

Abstract

Abstract:

Drug treatments for osteoarthritis are primarily targeted at relieving pain, improving joint function.Chronic persistent pain in osteoarthritis is often accompanied by neuropathic pain and central sensitization. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is used in the treatment of neuropathic pain through the descending pain modulatorysystem, and some studies have also found the anti-inflammatory activity of duloxetine in the treatment of pain. Duloxetine has been shown to be effective in relieving osteoarthritis pain in reported clinical trials and studies with good safety and tolerability profiles. This review mainly aimed at the related reports of duloxetine in the treatment of osteoarthritis pain.

Key words: Duloxetine hydrochloride, Osteoarthritis, Pain

Zheming Bao, Qing Shan, Chen Li, Mengli Chen. Advancement of duloxetine in treatment of osteoarthritis pain[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2021, 15(03): 318-323.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-134X.2021.03.009

https://zhgjwkzz.cma-cmc.com.cn/EN/Y2021/V15/I03/318

References 38

[1]	Kawarai Y, Orita S, Nakamura J, et al. Analgesic effect of duloxetine on an animal model of monosodium Iodoacetate-Induced hip osteoarthritis[J]. J Orthop Res, 2020, 38(2): 422-430.
[2]	Hunter DJ, Bierma-Zeinstra S. Osteoarthritis[J]. Lancet, 2019, 393(1182): 1745-1759.
[3]	GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and National incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet (London, England), 2018, 392(10159): 1789-1858.
[4]	Mcalindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis[J]. Osteoarthritis Cartilage, 2014, 22(3): 363-388.
[5]	Uchio Y, Enomoto H, Alev L, et al. A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis[J]. J Pain Res, 2018, 11: 809-821.
[6]	Bair MJ, Wu J, Damush TM, et al. Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients[J]. Psychosom Med, 2008, 70(8): 890-897.
[7]	Enteshari-Moghaddam A, Azami A, Isazadehfar K, et al. Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis[J]. Clin Rheumatol, 2019, 38(10): 2873-2880.
[8]	Chen L, Gong M, Liu G, et al. Efficacy and tolerability of duloxetine in patients with knee osteoarthritis: a meta-analysis of randomised controlled trials[J]. Intern Med J, 2019, 49(12): 1514-1523.
[9]	Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis[J]. Osteoarthritis Cartilage, 2019, 27(11): 1578-1589.
[10]	Fitzcharles MA, Lussier D, Shir Y. Management of chronic arthritis pain in the elderly[J]. Drugs Aging, 2010, 27(6): 471-490.
[11]	Van DJ, Schiphof D, Luijsterburg P, et al. Effectiveness and cost-effectiveness of duloxetine added to usual care for patients with chronic pain due to hip or knee osteoarthritis: protocol of a pragmatic open-label cluster randomised trial (the DUO trial)[J/OL]. BMJ Open, 2017, 7(9): e018661. doi：10.1136/bmjopen-2017-018661.
[12]	Havelin J, Imbert I, Cormier J, et al. Central sensitization and neuropathic features of ongoing pain in a rat model of advanced osteoarthritis[J]. J Pain, 2016, 17(3): 374-382.
[13]	Power JD, Perruccio AV, Gandhi R, et al. Neuropathic pain in end-stage hip and knee osteoarthritis: differential associations with patient-reported pain at rest and pain on activity[J]. Osteoarthritis Cartilage, 2018, 26(3): 363-369.
[14]	Sofat N, Harrison A, Russell MD, et al. The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis[J]. J Pain Res, 2017, 10：2437-2449.
[15]	Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents[J]. J Pharmacol Exp Ther, 2005, 312(2): 726-732.
[16]	Schaible HG. Mechanisms of chronic pain in osteoarthritis[J]. Curr Rheumatol Rep, 2012, 14(6): 549-556.
[17]	Mease PJ, Hanna S, Frakes EP, et al. Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment[J]. J Rheumatol, 2011, 38(8): 1546-1551.
[18]	Wang G, Bi L, Li X, et al. Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study[J]. Osteoarthritis Cartilage, 2017, 25(6): 832-838.
[19]	Ito S, Suto T, Saito S, et al. Repeated administration of duloxetine suppresses neuropathic pain by accumulating effects of noradrenaline in the spinal cord[J]. Anesth Analg, 2018, 126(1): 298-307.
[20]	Obata H. Analgesic mechanisms of antidepressants for neuropathic pain[J/OL]. Int J Mol Sci, 2017, 18(11): 2483. doi：10.3390/ijms18112483.
[21]	Alba-Delgado C, Mico JA, Sánchez-Blázquez P, et al. Analgesic antidepressants promote the responsiveness of locus coeruleus neurons to noxious stimulation: implications for neuropathic pain[J]. Pain, 2012, 153(7): 1438-1449.
[22]	Chen M, Hoshino H, Saito S, et al. Spinal dopaminergic involvement in the antihyperalgesic effect of antidepressants in a rat model of neuropathic pain[J]. Neurosci Lett, 2017, 649: 116-123.
[23]	Myers J, Wielage RC, Han B, et al. The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis[J/OL]. BMC Musculoskelet Disord, 2014, 15: 76. doi：10.1186/1471-2474-15-76.
[24]	Enomoto H, Fujikoshi S, Tsuji T, et al. Efficacy of duloxetine by prior NSAID use in the treatment of chronic osteoarthritis knee pain: a post hoc subgroup analysis of a randomized, placebo-controlled, phase 3 study in Japan[J]. J Orthop Sci, 2018, 23(6): 1019-1026.
[25]	Wang ZY, Shi SY, Li SJ, et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials[J]. Pain Med, 2015, 16(7): 1373-1385.
[26]	Yamashita T, Yamamoto S, Zhang J, et al. Duloxetine inhibits microglial P2X4 receptor function and alleviates neuropathic pain after peripheral nerve injury[J/OL]. PLoS One, 2016, 11(10): e0165189. doi：10.1371/journal.pone.0165189.
[27]	Kremer M, Yalcin I, Goumon Y, et al. A dual noradrenergic mechanism for the relief of neuropathic allodynia by the antidepressant drugs duloxetine and amitriptyline[J]. J Neurosci, 2018, 38(46): 9934-9954.
[28]	Choi HS, Park JH, Ahn JH, et al. The anti-inflammatory activity of duloxetine, a serotonin/norepinephrine reuptake inhibitor, prevents kainic acid-induced hippocampal neuronal death in mice[J]. J Neurol Sci, 2015, 358(1/2): 390-397.
[29]	Ohgi Y, Futamura T, Kikuchi T, et al. Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration[J]. Pharmacol Biochem Behav, 2013, 103(4): 853-859.
[30]	Bayram FO, Reis R, Tuncer B, et al. The importance of the structural similarity of drugs used for depression and inflammation，two comorbid diseases[J]. Curr Top Med Chem, 2018, 18(16): 1416-1421.
[31]	Wang G, Bi L, Li X, et al. Maintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension data[J/OL]. BMC Musculoskelet Disord, 2019, 20(1): 174.doi：10.1186/s12891-019-2527-y.
[32]	Itoh N, Tsuji T, Ishida M, et al. Response to duloxetine in patients with knee pain due to osteoarthritis: an exploratory post hoc analysis of a Japanese Phase III randomized study[J]. J Pain Res, 2018, 11: 2603-2616.
[33]	Fujii T, Takana K, Orita S, et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial[J]. Yonsei Med J, 2014, 55(5): 1379-1385.
[34]	Uchio Y, Enomoto H, Ishida M, et al. Safety and efficacy of duloxetine in Japanese patients with chronic knee pain due to osteoarthritis: an open-label, long-term, Phase III extension study[J]. J Pain Res, 2018, 11: 1391-1403.
[35]	Osani MC, Bannuru RR. Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis[J]. Korean J Intern Med, 2019, 34(5): 966-973.
[36]	Micca JL, Ruff D, Ahl J, et al. Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials[J/OL]. BMC Musculoskelet Disord, 2013, 14(1): 137. doi：10.1186/1471-2474-14-137.
[37]	Brown JP, Boulay LJ. Clinical experience with duloxetine in the management of chronic musculoskeletal pain. A focus on osteoarthritis of the knee[J]. Ther Adv Musculoskelet Dis, 2013, 5(6): 291-304.
[38]	Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants[J]. CNS Drugs, 2012, 26(1): 39-67.

Please choose a citation manager

Content to export